Effectiveness and cost‐effectiveness of 3‐monthly versus 6‐monthly monitoring of well‐controlled type 2 diabetes patients: a pragmatic randomised controlled patient‐preference equivalence trial in primary care ( <scp>EFFIMODI</scp> study)
Paulien R. Wermeling(University Medical Center Utrecht), Guy E.H.M. Rutten(University Medical Center Utrecht), G. Ardine de Wit(Utrecht University), Rebecca K. Stellato(University Medical Center Utrecht), Joline W. J. Beulens(Amsterdam University Medical Centers), K. J. Gorter(University Medical Center Utrecht)
Cited by 32
Related Papers
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k
Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups
|Social Science & Medicine|2001|648
Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study.
|Diabetes Care|2000|618
Is there an association between menopause status and sexual functioning?
|Menopause The Journal of The North American Menopause Society|2000|304